Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZAP70 | P43403 | 3/20 | 0.52 |
| ▸ | PARP1 | P09874 | 4/20 | 0.50 |
| ▸ | TNKS | O95271 | 3/20 | 0.50 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.50 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.40 |
| ▸ | TAF1 | P21675 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 4/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | QDPR | P09417 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.36 |
| ▸ | IL2 | P60568 | 1/20 | 0.36 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29874888 | 0.81 | BRD9 (0.52) | ZAP70PARP1TNKSTNKS2BRD9 | |
| SCHEMBL1725900 | 0.75 | BTK (0.39) | ZAP70JAK2ROCK2 | |
| SCHEMBL1046772 | 0.73 | ZAP70 (0.77) | ZAP70PARP1TNKSTNKS2SYK | |
| SCHEMBL25775893 | 0.72 | TNKS (0.47) | PARP1TNKSTNKS2BRD9P2RY14 | |
| SCHEMBL1048139 | 0.70 | ZAP70 (0.78) | ZAP70MAP4K1 | |
| SCHEMBL1046685 | 0.70 | ZAP70 (0.78) | ZAP70MAP4K1 | |
| SCHEMBL1048102 | 0.70 | ZAP70 (0.65) | ZAP70EGFRMAP4K1 | |
| SCHEMBL1048446 | 0.69 | ZAP70 (0.77) | ZAP70MAP4K1 | |
| SCHEMBL1043307 | 0.69 | ZAP70 (1.00) | ZAP70MAP4K1 | |
| SCHEMBL1049435 | 0.69 | ZAP70 (0.63) | ZAP70EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411404-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-29 | — | — | US | disclosed |
| EP-4058015-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411404-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | ZAP70 474/4885PARP1 3221/4885TNKS 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.